Ćeriman Krstić Vesna, Soldatović Ivan, Samardžić Natalija, Gajić Milija, Kontić Milica, Reljić Aleksandar, Savić Milan, Roksandić Milenković Marina, Jovanović Dragana
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Clinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Curr Issues Mol Biol. 2024 Nov 24;46(12):13431-13442. doi: 10.3390/cimb46120801.
Lung cancer represents the most common cause of cancer related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases (LM) have worse prognosis with an overall survival (OS) of three to six months. The aim of this study was to investigate long-term outcomes in patients with EGFR mutated (EGFRmut) lung adenocarcinoma as well as the presence of LM. (A total of 105 patients were included in the analysis). They were divided into two groups based on the presence of LM. OS was 13 months for the whole group and also 13 months for patients with and without LM. The 9-year survival rate for patients with and without LM was 12.5% and 3.4%, respectively. Further, the 9-year survival rate for the whole group of patients was 4.8%. There are few data about survival rates beyond 5 years for patients with locally advanced and metastatic EGFRmut NSCLC, mainly because patients with lung cancer rarely live for such a long time. Regarding patients with liver metastases, the results of our study showed similar outcomes compared to patients without LM. As these patients represent a significant number of patients, we need a wider range of therapeutic options. It might be that combination therapies represent a better therapeutic option.
肺癌是癌症相关死亡的最常见原因。非小细胞肺癌（NSCLC）合并肝转移（LM）的患者预后较差，总生存期（OS）为三到六个月。本研究的目的是调查表皮生长因子受体（EGFR）突变（EGFRmut）的肺腺癌患者以及存在肝转移的患者的长期预后情况。（共有105例患者纳入分析）。根据是否存在肝转移将他们分为两组。整个组的总生存期为13个月，有肝转移和无肝转移的患者总生存期也均为13个月。有肝转移和无肝转移患者的9年生存率分别为12.5%和3.4%。此外，整个组患者的9年生存率为4.8%。关于局部晚期和转移性EGFRmut非小细胞肺癌患者5年以上的生存率数据很少，主要是因为肺癌患者很少能活这么长时间。对于有肝转移的患者，我们的研究结果显示与无肝转移的患者预后相似。由于这类患者数量众多，我们需要更广泛的治疗选择。联合治疗可能是更好的治疗选择。
